Evidence map›Paper›PMID 41097795›Full record

ArticleCancers2025

Local Recurrence After Nephron Surgery: What to Do? An Italian Multicentric Registry.

Angelo Porreca, Filippo Marino, Davide De Marchi, Marco Giampaoli, Daniele D'Agostino, Francesca Simonetti, Antonio Amodeo, Paolo Corsi, Francesco Claps, Alessandro Crestani and 16 more

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Angelo PorrecaDepartment of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy.
Filippo MarinoDepartment of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy.ORCID 0000-0002-2908-6907
Davide De MarchiDepartment of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy.
Marco GiampaoliDepartment of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy.
Daniele D'AgostinoDepartment of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy.ORCID 0000-0002-6243-4985
Francesca SimonettiDepartment of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy.
Antonio AmodeoDepartment of Urology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.ORCID 0009-0009-2730-0402
Paolo CorsiDepartment of Urology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Francesco ClapsDepartment of Urology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
Alessandro CrestaniAzienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy.ORCID 0000-0001-7443-8740
Riccardo BertoloAzienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy.ORCID 0000-0003-0260-4601
Alessandro AntonelliAzienda Ospedaliera Universitaria Integrata Verona, 37126 Verona, Italy.
Fabrizio Di MaidaAzienda Ospedialiero-Universitaria Careggi, 50134 Firenze, Italy.ORCID 0000-0003-1885-4808
Andrea MinerviniAzienda Ospedialiero-Universitaria Careggi, 50134 Firenze, Italy.
Paolo ParmaAzienda Ospedaliera Carlo Poma, 46100 Mantova, Italy.
Roberto FalabellaOspedale S. Carlo, 85100 Potenza, Italy.
Stefano ZaramellaOspedale degli Infermi, 13875 Biella, Italy.
Francesco GrecoPoliclinico San Pietro, Gruppo San Donato, Ponte San Pietro, 24036 Bergamo, Italy.ORCID 0000-0002-9466-3029
Maria Chiara SighinolfiAgostino Gemelli University Polyclinic, 00136 Roma, Italy.
Bernardo RoccoAgostino Gemelli University Polyclinic, 00136 Roma, Italy.
Carmine SciorioClinica San Martino, 23864 Lecco, Italy.ORCID 0000-0001-6846-079X
Antonio CeliaOspedale San Bassiano, 36061 Bassano del Grappa, Italy.
Francesca Romana PruscianoOspedale SS. Annunziata, 74121 Taranto, Italy.ORCID 0009-0005-5965-9509
Pier Paolo PronteraOspedale SS. Annunziata, 74121 Taranto, Italy.ORCID 0000-0002-6321-946X
Gian Maria BusettoOspedali Riuniti di Foggia, Università di Foggia, 71122 Foggia, Italy.ORCID 0000-0002-7291-0316
Luca Di GianfrancescoDepartment of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy.ORCID 0000-0002-0564-7415

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectivesLocal recurrence (LR) in patients treated with surgery for renal cell carcinoma (RCC) remains a significant clinical challenge that requires thorough investigation. Our study aimed to identify the relative risk factors and explore the optimal clinical management of LR. MATERIALS AND

methodsWe conducted a non-randomized, observational, retrospective multicentric registry involving multiple Italian urological centers. We included patients treated with surgery (either nephron-sparing or radical nephrectomy) who later developed LR, defined as recurrence in the ipsilateral kidney or renal fossa. Patients with hereditary syndromes or metastatic disease at the time of LR diagnosis were excluded.

resultsWe reported 135 cases of LR with the following characteristics: most primary lesions were monofocal (85.7%), with a median size of 42 mm (23-53), the median R.E.N.A.L. score was 7 (6-8), and the median Padua score was 7 (6-9). Patients were treated with robot-assisted techniques in 59% of cases, laparoscopic surgery in 32.4%, and open surgery in 8.6%. Nephron-sparing surgery was performed in 75.2% of cases. Ischemia occurred in 61% of the cases, with a median ischemia time of 21 min (15.5-24). Intraoperative complications occurred in 3.8% of cases, while postoperative complications were reported in 13.8%, all of which were grade ≤3 according to the Clavien-Dindo classification. The primary tumors were pT1a in 43.5% of cases, pT1b in 26.3%, pT2 in 14.7% and pT3 in 15.5%. Histologically, 84% of cases were clear cell, 11.3% papillary type 1 or 2, and 3.7% chromophobe. Sarcomatoid/rhabdoid variants were present in 10.5% of cases. The median rate of LR was 1.3% (range 0.2-3.6), while the median time to LR was 18 months (12-39). LR occurred in the ipsilateral kidney in 70.5% of cases and in the ipsilateral renal fossa in 29.5%. The median rate of PSM in LR cases at initial surgery was 2.4% (range 0-4.3), while the median rate of negative surgical margin (NSM) in LR cases at initial surgery was 0.1 (0-0.3). Following LR diagnosis, most patients (49.2%) underwent surgery, 29.1% received cryoablation or radiotherapy, 17.1% received systemic treatment alone, and 4.6% followed a watchful waiting/active surveillance approach. At a median follow-up of 62 months, the highest oncological control in terms of 5-year cancer-specific survival and overall survival rates was achieved in surgically treated patients. The PSM, the histological variant, and their combination were found to be independent variables correlated with the occurrence of LR, with relative risks of 3.62, 2.71, and 8.12, respectively.

conclusionsLR after nephron-sparing or radical nephrectomy represents a significant clinical dilemma. Known risk factors are not always sufficient to predict recurrence, emphasizing the necessity of consistent radiological follow-up per guideline recommendations. Early detection of recurrence and a multidisciplinary approach involving expert centers are crucial for optimizing patient outcomes.

Indexed as

local recurrencepartial nephrectomypositive surgical marginprognostic factorradical nephrectomyrenal cell carcinomareview

Identifiers

PMID41097795
PMCPMC12523260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.